Supplementary Online Content

Size: px
Start display at page:

Download "Supplementary Online Content"

Transcription

1 Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population. JAMA. doi: /jama eappendix 1. Methods eappendix 2. Results etable 1. Acute HIV Infection Detection by Assay The STOP Study, September 2011-October 2013 etable 2. HIV Testing Results for Patients With False-Negative Pooled HIV RNA Test Results The STOP Study, September 2011-October 2013 efigure. Sequence of Appearance of Laboratory Markers for HIV-1 Infection ereferences This supplementary material has been provided by the authors to give readers additional information about their work.

2 eappendix 1. Methods The advantages of Multispot as a confirmatory test include that (1) it can differentiate HIV-1 and HIV-2 antibodies, (2) it has fewer indeterminate results, (3) it can be performed in all clinical labs, and (4) it is rapid. In the primary analysis, acute HIV infection required only a negative rapid HIV test result to demonstrate the absence of HIV antibody as this approach is consistent with how health departments and testing sites approach acute infection. In a supplemental analysis (see supplemental results), a serological definition of acute HIV infection was used that required both a negative rapid test and a negative or indeterminate Multispot test result 1. As false negative results can occur with rapid HIV tests, this more stringent serological definition of acute HIV infection was used to quantify how many false negative rapid HIV tests may have occurred.

3 eappendix 2. Results All acute infections detected by HIV Ag/Ab combination testing were also tested with the Multispot antibody assay. Among these 134 acute infections, 97 (72%) specimens were negative on Multispot confirmatory testing (anti-hiv-1 IgG antibody was not detected), 10 (7%) specimens were HIV-1 indeterminate, and 27 (20%) specimens were reactive (anti-hiv-1 IgG antibody was detected). Among these 27 Multispot reactive results, 17 specimens were consistent with early or acute infection based on other test results, including the following (not mutually exclusive): a documented negative HIV test result in the previous 6 months (n=11), an HIV-1 viral load >500,000 copies/ml (n=10), or a negative Western blot / IFA result (n=2). For the remaining 10 Multispot reactive results, a false-negative rapid test result in individuals with established HIV infection could not be ruled out. Among the 93 false-positive Ag/Ab combination test results, Multispot testing on two specimens was HIV-1 indeterminate, two specimens were HIV-2 reactive (but negative on further HIV-2 testing), and the remaining 89 specimens were negative.

4 etable 1. Acute HIV Infection Detection by Assay The STOP Study, September 2011 October 2013 HIV Ag/Ab Combination Assay Pooled HIV-1 RNA Testing Detectable 130 (77.4%) 4 (2.4%) Nonreactive 34 (20.2%) 0 (0%) Ag/Ab = Antigen/Antibody

5 etable 2. HIV testing results for patients with false negative pooled HIV RNA test results The STOP Study, September 2011 October 2013 Patient RNA1 HIV Ag/Ab Combination Assay S/CO = 2.43 Pooled HIV RNA Testing (pool= 10) Viral load (copies/ml) Other Antibody Results 45 Rapid HIV test negative Multispot HIV-1 reactive WB positive IFA positive Comments Evidence of elite HIV-1 control without antiretrovirals* RNA2 S/CO = 5.36 (pool= 10) 59 Rapid HIV test negative Multispot HIV-1 reactive IFA positive WB positive Evidence of elite HIV-1 control without antiretrovirals* RNA3 S/CO = (pool= 16) <400 Rapid HIV test negative Multispot HIV-1 reactive WB positive Individual qualitative HIV-1 RNA detected RNA4 S/CO = 1.26 (pool= 80) 120,310 Rapid HIV test negative Multispot nonreactive WB negative Likely RNA testing lab error Ag/Ab = Antigen/Antibody; S/CO = signal-to-cut-off ratio; WB = Western blot; IFA = HIV-1 immunofluorescent assay *A small proportion (< 0.1%) of HIV-infected persons have undetectable HIV viremia (HIV RNA <50 copies/ml) without antiretrovirals and these patients have been classified as elite controllers. Conventional HIV RNA assays (including pooled HIV RNA testing) can be undetectable in these patients and ultrasensitive HIV RNA assays are often required to confirm HIV infection.

6 efigure. Sequence of appearance of laboratory markers for HIV-1 infection HIV RNA (plasma) HIV Antibody HIV p24 Antigen Infection Days Detection of HIV RNA HIV p24 Antigen* HIV IgG Antibody by rapid HIV test and Western blot Phase of Infection Acute HIV Infection Established HIV Infection * Detectable by lab-based HIV Ag/Ab combination immunoassays Note. Units for vertical axis are not noted because their magnitude differs for RNA, p24 antigen, and antibody

7 ereferences. 1. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at Published June 27, Accessed July 3, 2014.

Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016

Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016 New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new

More information

Adventures in Discordance- HIV Testing

Adventures in Discordance- HIV Testing Anne Gaynor, PhD On behalf of Monica M. Parker, PhD Director, Bloodborne Viruses Laboratory Wadsworth Center, NYSDOH Adventures in Discordance- HIV Testing HIV Laboratory Testing Algorithm HIV-1/2 antigen/antibody

More information

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC) HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC

More information

HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch

HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch HIV Test Technologies, Best Practices, and New Algorithm Jenny R. McFarlane DSHS HIV Prevention and Care Branch Testing History 1985 1 st Gen HIV-1 IA 1987 HIV-1 WB 1990 HIV-2 IA HIV-1 IA DBS 1991 2 nd

More information

HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM. Version

HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM. Version 1 HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM Event Name: Event Time Period: ADULT HIV 900 (AIDS.gov 12/31/2015) HIV Lifelong HIV (human immunodeficiency virus) is a retrovirus

More information

Diagnosis and Management of Acute HIV

Diagnosis and Management of Acute HIV Diagnosis and Management of Acute HIV A New HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV, this committee

More information

List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation

List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation Alere (honoraria) List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation testing algorithm Interpret challenging

More information

1 st and 2 nd Generation EIA

1 st and 2 nd Generation EIA HIV Diagnostic Tests Bernard M. Branson, M.D. Associate D irector for Laboratory D iagnostics Division of HIV/AIDS Prevention Centers for D isease Control & Prevention The views expressed in this presentation

More information

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What

More information

Diagnostic Tests for HIV

Diagnostic Tests for HIV Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,

More information

New HIV Tests and Algorithm: A change we can believe in

New HIV Tests and Algorithm: A change we can believe in New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be

More information

HIV Testing Technology and the Latest Algorithm

HIV Testing Technology and the Latest Algorithm HIV Testing Technology and the Latest Algorithm David Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene HIV Testing has changed over time Patients with

More information

AccuSet Anti-HIV-1 Mixed Titer Performance Panel

AccuSet Anti-HIV-1 Mixed Titer Performance Panel signal to cut-off (s/co) DATA SHEET OVERVIEW PRB205(M3) is a modified 16-member panel originating from Anti- HIV-1 Mixed Titer PRB205(M2). Panel members 3, 5, 6, 17, 21, 22, 23, 24, and 25 from the original

More information

AccuSet Anti-HIV-1 Mixed Titer Performance Panel

AccuSet Anti-HIV-1 Mixed Titer Performance Panel PACKAGE INSERT PRB205(M3) / (0800-0379) INTENDED USE The Performance Panel PRB205(M3) / (0800-0379) is intended for use by diagnostics manufacturers and clinical laboratorians to evaluate their HIV-1 test

More information

Using all the data: Immunoassay signal-to-cutoff values provide useful information that should be considered in HIV diagnostic

Using all the data: Immunoassay signal-to-cutoff values provide useful information that should be considered in HIV diagnostic Using all the data: Immunoassay signal-to-cutoff values provide useful information that should be considered in HIV diagnostic algorithms KP Delaney, M Pentella, B Bennett, and K Landgraf for the CDC/APHL

More information

Complicated viral infections

Complicated viral infections Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western

More information

Human Immunodeficiency Virus Serology

Human Immunodeficiency Virus Serology Participant No: _ Human Immunodeficiency Virus Serology Survey No: RT :20 Please print the document labelled Clinical Notes & Test Instructions and enter your results via myqap. Kit Information Please

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content El-Sadr WM, Donnell D, Beauchamp G, et al. Financial incentives for linkage to care and viral suppression among HIV-positive patients: a randomized clinical trial (HPTN 065)

More information

FDA Reentry Guidance

FDA Reentry Guidance FDA Reentry Guidance T. cruzi - Chagas, Hepatitis C and HIV Wednesday 6/6/18 Doug Denyer O Dina Hurlburt, SBB(ASCP)CM Outline Impact to Clients Review of FDA Guidance Documents Reentry Request Process

More information

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention New Generation of Nucleic Acid Testing Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Percentage (%) Persons Living with Diagnosed or Undiagnosed HIV Infection

More information

2018 HIV and HCV Diagnostic Testing Survey

2018 HIV and HCV Diagnostic Testing Survey 2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will

More information

Technical Bulletin No. 104b

Technical Bulletin No. 104b CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 104b June 22, 2016 Update to Guidelines for Diagnosing HIV Infection CPAL s Testing Algorithm for Diagnostic HIV Testing HIV Geenius

More information

Overview of HIV Testing Practices and Technology

Overview of HIV Testing Practices and Technology Overview of HIV Testing Practices and Technology 2019 HIV Diagnostics Conference March 25 th, 2019 Michele Owen, Ph.D National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease

More information

Obstetrics and HIV An Update. Jennifer Van Horn MD University of Utah

Obstetrics and HIV An Update. Jennifer Van Horn MD University of Utah Obstetrics and HIV An Update Jennifer Van Horn MD University of Utah Obstetrics and HIV Perinatal transmission Testing Antiretroviral therapy Antepartum management Intrapartum management Postpartum management

More information

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Knox DC, Anderson PL, Harrigan PR, Tan DHS. Multidrug-resistant

More information

The Latest in HIV Tests: What Do the Results Mean?

The Latest in HIV Tests: What Do the Results Mean? The Latest in HIV Tests: What Do the Results Mean? Bernard M. Branson MD Principal Consultant, Scientific Affairs LLC Atlanta, Georgia Objectives At the end of this workshop, participants will be able

More information

Technical Bulletin No. 104a

Technical Bulletin No. 104a CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 104a April 22, 2014 Update to Guidelines for Diagnosing HIV Infection - CPAL s Testing Algorithm for Diagnostic HIV Testing Contact:

More information

HEALTH. Re: Interim Guidelines for Laboratories on the use of a new Diagnostic Testing Algorithm for Human Immunodeficiency Virus (HIV) Infection

HEALTH. Re: Interim Guidelines for Laboratories on the use of a new Diagnostic Testing Algorithm for Human Immunodeficiency Virus (HIV) Infection ===========ir ~~!!~~fk li=:='========= Nirav R. Shah, M.D., M.P.H. Commissioner May 16, 2013 HEALTH Sue Kelly Executive Deputy Commissioner Re: Interim Guidelines for Laboratories on the use of a new Diagnostic

More information

Expression of HIV-1 Markers During Progression of Infection E E E Days Since 1st Bleed

Expression of HIV-1 Markers During Progression of Infection E E E Days Since 1st Bleed Seroconversion OVERVIEW HIV-1 AccuVert TM Seroconversion PRB970 is a 4 member, 1.0 ml per vial panel of undiluted, naturally-occurring plasma samples. members represent serial bleeds collected from a single

More information

HIV-1 Seroconversion Panel

HIV-1 Seroconversion Panel OVERVIEW This Data Sheet contains test results specific for HIV-1. s are undiluted aliquots from plasma units collected from a single donor. No preservatives were added. CAUTION: Potentially infectious

More information

HIV Guideline Sakchai Dettrairat

HIV Guideline Sakchai Dettrairat HIV Guideline 2016 Sakchai Dettrairat Division of Clinical Immunology Department of Medical Technology Faculty of Associated Medical Sciences Chiang Mai University Appearance of HIV markers in early HIV

More information

APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018

APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018 APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018 Shipping and Submission Instructions Thank you for participating as a submitting

More information

HIV-1 Seroconversion Panel PRB964

HIV-1 Seroconversion Panel PRB964 A SERACARE PANEL PRODUCT Seroconversion INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This is intended for use by diagnostics manufacturers and clinical

More information

RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis

RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis 1 B R E N D A N M C M U L L A N I N F E C T I O U S D I S E A S E S, S Y D N E Y C H I L D R E N S H O S P I T A L S C H O O L O F W O

More information

Diagnosing HIV Infection AMNERIS E. LUQUE, M.D. PROFESSOR OF MEDICINE/INFECTIOUS DISEASES MEDICAL DIRECTOR, PARKLAND HIV SERVICES

Diagnosing HIV Infection AMNERIS E. LUQUE, M.D. PROFESSOR OF MEDICINE/INFECTIOUS DISEASES MEDICAL DIRECTOR, PARKLAND HIV SERVICES Diagnosing HIV Infection AMNERIS E. LUQUE, M.D. PROFESSOR OF MEDICINE/INFECTIOUS DISEASES MEDICAL DIRECTOR, PARKLAND HIV SERVICES Disclosures None Objectives 1. Outline the CDC recommendations for HIV

More information

HIV Diagnostic Testing

HIV Diagnostic Testing In The name of God HIV Diagnostic Testing By : Dr. Shahzamani PhD of Medical virology Purpose of HIV Testing To identify asymptomatic individuals To diagnose HIV infection in those who practice high risk

More information

AccuVert HIV-1 Seroconversion Panel PRB974 ( )

AccuVert HIV-1 Seroconversion Panel PRB974 ( ) PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers

More information

A Summary of Clinical Evidence

A Summary of Clinical Evidence A Summary of Clinical Evidence Supporting the use of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test to assist in the diagnosis of Human Immunodeficiency Virus (HIV) TAP HERE TO SEE THE PRODUCTS Table

More information

A Case of False-Positive Test Results in a Pregnant Woman of Unknown HIV Status at Delivery

A Case of False-Positive Test Results in a Pregnant Woman of Unknown HIV Status at Delivery A Case of False-Positive Test Results in a Pregnant Woman of Unknown HIV Status at Delivery Pascale Akl, MD, 1 Kenneth E. Blick, PhD 1* Lab Med Spring 2014;45:259-263 DOI: 10.1309/LMAAGVXK05LUWOQN ABSTRACT

More information

Case Definition and Lab Tests

Case Definition and Lab Tests Chapter 7 Case Definition and Lab Tests 7-1 Test types Laboratory tests are available to diagnose HIV infection, as well as to monitor health status after HIV diagnosis. Diagnostic tests look for an immune

More information

2006 HIV Diagnostics Survey

2006 HIV Diagnostics Survey Public Health Laboratory Issues in Brief: 2006 HIV Diagnostics Survey Association of Public Health Laboratories November 2007 Background Nearly 20 years ago, the Association of Public Health Laboratories

More information

The HIV Bridge Algorithm: Linking Point-of-Contact, Laboratory and Patient Care HIV Diagnostic Conference March 24, 2010

The HIV Bridge Algorithm: Linking Point-of-Contact, Laboratory and Patient Care HIV Diagnostic Conference March 24, 2010 The HIV Bridge Algorithm: Linking Point-of-Contact, Laboratory and Patient Care 2010 HIV Diagnostic Conference March 24, 2010 Berry Bennett, MPH Retrovirology Section Chief Florida Bureau of Laboratories

More information

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental

More information

Evolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention

Evolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like

More information

HIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES

HIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES ISSUES IN BRIEF: MEMBER SURVEY OF HIV ASSAY USE ASSOCIATION OF PUBLIC HEALTH LABORATORIES MARCH 2010 HIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES Twenty years ago, the Association of Public Health

More information

Routine HIV Testing Community of Practice Session #2

Routine HIV Testing Community of Practice Session #2 Routine HIV Testing Community of Practice Session #2 Presenters: Denver Prevention Training Center Broward Community & Family Health Centers, Inc. 20 March 2016 Communities of Practice Routine HIV Testing

More information

Maximizing Cornea and Tissue Donation through Specimen Quality

Maximizing Cornea and Tissue Donation through Specimen Quality Maximizing Cornea and Tissue Donation through Specimen Quality Robert W. Bresler, Sydney D. Gastreich, Elias G. Koulouriotis, Linda S. Martin, Susan Diane Brockmeier, Chak-Sum Ho, PhD Abstract Purpose:

More information

Ability to Identify Acute HIV Infections from Surveillance Data Varies by Diagnostic Testing Algorithm

Ability to Identify Acute HIV Infections from Surveillance Data Varies by Diagnostic Testing Algorithm Ability to Identify Acute HIV Infections from Surveillance Data Varies by Diagnostic Testing Algorithm Laurie Linley, MPH; Anne H. Peruski, MPH, PhD; Richard M. Selik, MD; Kevin P. Delaney, MPH, PhD; Alexandra

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Jänne PA, van den Heuvel MM, Barlesi F, et al. Effect of selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRASmutant

More information

Immunologic Methods in Diagnosis of HIV Infection. Tehran Medical Sciences Branch, Islamic Azad

Immunologic Methods in Diagnosis of HIV Infection. Tehran Medical Sciences Branch, Islamic Azad Immunologic Methods in Diagnosis of HIV Infection M Parsania, Ph.D. Tehran Medical Sciences Branch, Islamic Azad University Retroviridae Retroviruses (family Retroviridae) id ) are enveloped, single stranded

More information

Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform*

Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* HIV immunoassays grouped by generation, platform, and CLIA complexity + Advantages

More information

HIV Serology Quality Assessment Program Revised Summary for Panel HIVSER 2017Oct27

HIV Serology Quality Assessment Program Revised Summary for Panel HIVSER 2017Oct27 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Revised

More information

EDITORIAL Issue Fifteen, August 2003

EDITORIAL Issue Fifteen, August 2003 EDITORIAL, August 2003 The featured article in this edition is Laboratory diagnosis for infection with Human Immunodeficiency virus (HIV) by Dr John Vivian Wells and Richard Allen. The authors combined

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.

More information

SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World

SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World MIT OpenCourseWare http://ocw.mit.edu SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World Spring 2009 For information about citing these materials or our

More information

HIV-1 Seroconversion Panel PRB975

HIV-1 Seroconversion Panel PRB975 Seroconversion OVERVIEW is a five member HIV Seroconversion collected from a single donor over a 14 day period in 2002, prior to antibody seroconversion. -03 is a challenging sample for HIV RNA assays,

More information

Minimum Standards for Laboratories in SADC Regions

Minimum Standards for Laboratories in SADC Regions Minimum Standards for Laboratories in SADC Regions Facilitator Guide Day 2 Minimum Laboratory Testing Standards: Diagnosis of HIV Infection at the NRL Table of Contents 1. Learner Information... 4 2. About

More information

Spectrum of false positivity for the fourth generation human immunodeficiency virus diagnostic tests

Spectrum of false positivity for the fourth generation human immunodeficiency virus diagnostic tests DOI 10.1186/s12981-015-0086-3 AIDS Research and Therapy CASE REPORT Spectrum of false positivity for the fourth generation human immunodeficiency virus diagnostic tests Peter Liu 1*, Patrick Jackson 2,

More information

High Rate of Missed HIV Infections in Individuals With Indeterminate or Negative HIV Western Blots Based on Current HIV Testing Algorithm in China

High Rate of Missed HIV Infections in Individuals With Indeterminate or Negative HIV Western Blots Based on Current HIV Testing Algorithm in China Journal of Medical Virology 88:1462 1466 (2016) High Rate of Missed HIV Infections in Individuals With Indeterminate or Negative HIV Western Blots Based on Current HIV Testing Algorithm in China Man-Qing

More information

SEROLOGICAL DIAGNOSIS OF VIRAL INFECTIONS:

SEROLOGICAL DIAGNOSIS OF VIRAL INFECTIONS: SEROLOGICAL DIAGNOSIS OF VIRAL INFECTIONS: POSSIBILITIES OF SEROLOGICAL DIAGNOSIS TYPES OF SEROLOGICAL REACTIONS SEROLOGICAL REACTIONS Ag-Ab reactions used for the detection of unknown Ag or Ab, in vitro

More information

Shared Service Success

Shared Service Success Shared Service Success Six Years of HIV Nucleic Acid Testing for US Public Health Laboratories A Gaynor, M Parker, B Bennett, L. Wesolowski, S. Ethridge, T. Sullivan, S. Fordan, K. Wroblewski Conflict

More information

Clinical HIV-2 Viral Load Testing of a Large Population of HIV-2 Infected Individuals

Clinical HIV-2 Viral Load Testing of a Large Population of HIV-2 Infected Individuals Clinical HIV-2 Viral Load Testing of a Large Population of HIV-2 Infected Individuals Linda M. Styer Wadsworth Center, NYSDOH ** The authors have no conflicts of interest to disclose ** HIV-2 viral load

More information

NEW CHALLENGES FOR ACCURATE HIV-1 DIAGNOSIS ALL BELGIAN AIDS REFERENCE LABORATORIES KAROLIEN STOFFELS (ARL VUB STP) & FIEN VANROYE (ARL ITM)

NEW CHALLENGES FOR ACCURATE HIV-1 DIAGNOSIS ALL BELGIAN AIDS REFERENCE LABORATORIES KAROLIEN STOFFELS (ARL VUB STP) & FIEN VANROYE (ARL ITM) NEW CHALLENGES FOR ACCURATE HIV-1 DIAGNOSIS ALL BELGIAN AIDS REFERENCE LABORATORIES KAROLIEN STOFFELS (ARL VUB STP) & FIEN VANROYE (ARL ITM) 30 NOVEMBER 2018, BRUGGE 0 NEW CHALLENGES FOR ACCURATE HIV-1

More information

ISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer

ISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer ISBT WP-TTID Annual Report for Subgroup on Virology Drs. Michael Busch, Kurt Roth and Susan Stramer Questionnaire on NAT Screening of Blood Donations for an International Forum on 10 years of NAT Screening

More information

HIV-1 Seroconversion Panel

HIV-1 Seroconversion Panel A SERACARE PANEL PRODUCT Seroconversion INTENDED USE The Seroconversion is a group of serial bleeds from an individual plasma donor during seroconversion. This is intended for use by diagnostics manufacturers

More information

The Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013

The Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013 The Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013 Christopher Bentsen, M.S.,RAC, FRAPS Bio-Rad Laboratories, Redmond,

More information

How are testing technologies used to diagnose HIV infection?

How are testing technologies used to diagnose HIV infection? HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including where the test is conducted,

More information

Potential Effect of Alternative HIV Testing Algorithms on HIV Case Surveillance

Potential Effect of Alternative HIV Testing Algorithms on HIV Case Surveillance Potential Effect of Alternative HIV Testing Algorithms on HIV Case Surveillance Kristen Mahle, MPH HIV Incidence & Case Surveillance Branch DHAP, NCHHSTP, CDC 2010 Diagnostics Conference March 24, 2010

More information

Minimum Standards for Laboratories in SADC Regions

Minimum Standards for Laboratories in SADC Regions Minimum Standards for Laboratories in SADC Regions Participant Guide Day 2 Minimum Laboratory Testing Standards: Diagnosis of HIV Infection at the NRL Table of Contents 1. Learner Information... 4 2. About

More information

4.6. How to test - testing strategy HCV. Decision-making tables PICO 4

4.6. How to test - testing strategy HCV. Decision-making tables PICO 4 4.6. How to test - testing strategy HCV Decision-making tables PICO 4 Testing strategy to ascertain exposure to HCV: Among persons identified for hepatitis C testing, what is the best testing strategy

More information

Viral Hepatitis Diagnosis and Management

Viral Hepatitis Diagnosis and Management Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes:

More information

The Evolving Landscape of HIV Prevention and Diagnosis

The Evolving Landscape of HIV Prevention and Diagnosis The Evolving Landscape of HIV Prevention and Diagnosis Jenny R. McFarlane Texas Department of State Health Services HIV/STD/TB/Viral Hepatitis Unit Is it okay if we just talk? NHAS: A Call to ACT Reduce

More information

HIV Screening & Consent for Testing

HIV Screening & Consent for Testing 1. Algorithm for HIV Screening 2. Screening & Consent for HIV Testing a. Offering testing b. Counseling on HIV Risk Factors c. Pre-test Counseling d. Post-test Counseling 1. Positive Result 2. Preliminary

More information

HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28

HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28

More information

TEST REQUEST INFORMATION- VIROLOGY

TEST REQUEST INFORMATION- VIROLOGY Chlamydia/ Gonorrhea Nucleic Acid Amplification VC75 Qualitative Nucleic Acid Amplification SPECIMEN: Genital swab or first catch urine CONTAINER:GEN-PROBE APTIMA 2 Combo swab transport tube or urine transport

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Sussman JB, Kerr EA, Saini SD, et al. Rates of deintensification of blood pressure and glycemic medication treatment based on levels of control and life expectancy in older

More information

Documentation, Codebook, and Frequencies

Documentation, Codebook, and Frequencies 2 Documentation, Codebook, and Frequencies Laboratory Component: Hepatitis B: core antibody, surface antibody and surface antigen; Hepatitis C: confirmed antibody; Hepatitis D antibody Survey Years: 2003

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Schmidt B, Whyte RK, Asztalos EV, et al; for the Canadian Oxygen Trial (COT) Group. Effects of targeting higher vs lower arterial oxygen saturations on death or disability

More information

HIV-1 Seroconversion Panel PRB973

HIV-1 Seroconversion Panel PRB973 A SERACARE PANEL PRODUCT INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers and clinical laboratorians

More information

NAT Screening of Blood Donations in NBC, TRCS

NAT Screening of Blood Donations in NBC, TRCS IPFA/PEI, Italy NAT Screening of Blood Donations in NBC, TRCS 2000-2001 Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine

More information

AccuSet HIV-1/2 Performance Panel

AccuSet HIV-1/2 Performance Panel OVERVIEW AccuSet HIV-1/2 (0800-0380) is a 13-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent bleeds from multiple

More information

Comparison of the Geenius HIV-1/2 Supplemental Assay and HIV-1 Western blot for HIV rapid test confirmation from dried blood spots

Comparison of the Geenius HIV-1/2 Supplemental Assay and HIV-1 Western blot for HIV rapid test confirmation from dried blood spots Comparison of the Geenius HIV-1/2 Supplemental Assay and HIV-1 Western blot for HIV rapid test confirmation from dried blood spots Timothy J. Sullivan Bloodborne Viruses Laboratory Wadsworth Center, NYSDOH

More information

Mom Chandara, Msc, NIPH Team

Mom Chandara, Msc, NIPH Team Mom Chandara, Msc, NIPH Team EXTERNAL QUALITY ASSESSMENTS (EQAS) EQA refers to a system in which laboratory results are scrutinized objectively by an outside agency in order to get a general impression

More information

Confirmatory Testing Algorithm. Routine Donor Testing Algorithm

Confirmatory Testing Algorithm. Routine Donor Testing Algorithm Confirmatory Testing Algorithm Blood Confirmatory ABO/Rh Beckman Coulter PK-ABO/Rh Immucor NEO ABO/Rh Immucor NEO ABO/Rh Immucor Manual ABO/Rh Typing Immucor Manual ABO/Rh Typing Discrepancy Resolution

More information

Epidemiologists and Laboratory Science

Epidemiologists and Laboratory Science Epidemiologists and Laboratory Science Najib Aziz, M.D. Adjunct Associate Professor Department of Epidemiology UCLA, Fielding School of Public Health January 2014 Introduction: Advance in the laboratory

More information

Appendix B: Provincial Case Definitions for Reportable Diseases

Appendix B: Provincial Case Definitions for Reportable Diseases Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Hemorrhagic fevers caused by: i) Ebola virus and ii) Marburg virus and iii) Other viral causes including

More information

An Evaluation of Qualitative HIV-2 RNA Referral Testing

An Evaluation of Qualitative HIV-2 RNA Referral Testing An Evaluation of Qualitative HIV-2 RNA Referral Testing Linda M. Styer, Anne Gaynor, Laura Wesolowski, Steve Ethridge and Monica M. Parker Wadsworth Center, NYSDOH; APHL; Division of HIV/AIDS Prevention,

More information

AdvaMedDx Value Assessment Framework in Practice

AdvaMedDx Value Assessment Framework in Practice AdvaMedDx Value Assessment Framework in Practice Application of the Comprehensive Assessment of the Value of Diagnostic Technologies Framework to Abbott s 4th Generation ARCHITECT HIV Antigen/Antibody

More information

Research Article Decision on conducting HCV Immunoblot and HCV Viral Load Tests Dependent upon the Result of the Screening Tests

Research Article Decision on conducting HCV Immunoblot and HCV Viral Load Tests Dependent upon the Result of the Screening Tests IBIMA Publishing Journal of Virology & Microbiology http://www.ibimapublishing.com/journals/jvm/jvm.html Vol. 2013 (2013), Article ID 332501, 7 pages DOI: 10.5171/2013.332501 Research Article Decision

More information

HIV testing technologies

HIV testing technologies HIV testing technologies HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including

More information

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

HIV 101: Fundamentals of HIV Infection

HIV 101: Fundamentals of HIV Infection HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able

More information

AccuVert HIV-1 Seroconversion Panel PRB955 ( ) / Batch #

AccuVert HIV-1 Seroconversion Panel PRB955 ( ) / Batch # Signal to cutoff (s/co) Copies per ml (c/ml) OVERVIEW AccuVert is a 5-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent

More information

Objectives. Seven days of separation. Clinical situation a transplant. The Donor COOMBS MD PHD 1. Laboratory Diagnosis & Monitoring of HIV Infection

Objectives. Seven days of separation. Clinical situation a transplant. The Donor COOMBS MD PHD 1. Laboratory Diagnosis & Monitoring of HIV Infection Laboratory Diagnosis & Monitoring of HIV Infection An Introduction to Diagnostic HIV Testing Robert W Coombs MD, PhD, FRCPC Professor, Departments of Laboratory Medicine & Medicine University of Washington,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. doi:10.1001/jama.2018.4853

More information